Guideline
Guideline for the prevention and treatment of hepatitis C (2022 version)
Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association
Published 2022-12-20
Cite as Chin J Hepatol, 2022, 30(12): 1332-1348. DOI: 10.3760/cma.j.cn501113-20221220-00605
Abstract
In order to update the prevention, diagnosis and antiviral therapy for hepatitis C and to achieve the World Health Organization's goal of eliminating viral hepatitis as a public health threat by 2030; Chinese Medical Association, the Chinese Society of Hepatology, and the Society of Infectious Diseases organized relevant experts in 2019 to update the guidelines for the prevention and treatment of hepatitis C (2019 version) based on the basic and clinical research progress of hepatitis C infection, combined with the present situation of our country, so as to provide an important basis for the prevention, diagnosis and treatment of hepatitis C. Since the end of 2019, the screening and management strategy of hepatitis C has been further updated. More and more direct antiviral agents, especially pan genotypic agents including those developed and produced by domestic enterprises, have been included in the national basic medical insurance directory. The accessibility of drugs has significantly increased. In 2022, experts updated the recommendations on prevention and treatment again.
Key words:
Hepatitis C; Treatment; Prevention; Guideline
Contributor Information
Chinese Society of Hepatology and Chinese Society of Infectious Diseases
Chinese Medical Association